What diseases does Pemetinib treat? How much does it cost? Is it included in medical insurance?

Pemetinib is an innovative drug used to treat certain types of cancer and belongs to a class of drugs called kinase inhibitors. The drug has shown unique efficacy in treating adult patients who have received previous treatment, particularly those with cholangiocarcinoma that has spread to nearby tissue or other parts of the body and cannot be removed with surgery.

Cholangiocarcinoma is a malignant tumor originating from bile duct epithelial cells. It is highly aggressive and has no obvious early symptoms, resulting in many patients being diagnosed at an advanced stage. The emergence of pemetinib brings new treatment hope to these patients. It inhibits the growth and spread of cancer cells by blocking the action of an abnormal protein called fibroblast growth factor receptor (FGFR) that signals cancer cells to proliferate. This targeted treatment mechanism allows pemetinib to accurately attack cancer cells while minimizing damage to healthy cells.

In addition, pemetinib is used to treat adult patients with myeloid/lymphoid neoplasm (MLN), a type of blood cancer, that has not improved or has relapsed after other treatments. For such patients, pemetinib also shows good therapeutic potential. Through its unique kinase inhibitory effect, it can help control disease progression and prolong patient survival.

Pemetinib is usually taken orally, and patients need to strictly follow the dosage and course of treatment under the guidance of a doctor. During the medication process, patients may experience some side effects, such as fatigue, nausea, vomiting, etc., but these side effects can usually be effectively managed under the guidance of a doctor. Overall, pemetinib, as a targeted therapy, provides new treatment options for patients with cholangiocarcinoma and myeloid/lymphoid tumors, helping them better cope with the challenges of the disease.

Pemetinib has now been launched in Chinese hospitals, and patients can directly purchase the original version of the drug. However, unfortunately, pemetinib has not yet been included in the domestically marketed medical insurance reimbursement items. Its specification is 4.5mg 14 tablets, and the market price is about 30,000 yuan. It is reported that the original research version and the generic version coexist in foreign markets. The original research version of 13.5mg 14 tablets is priced as high as 72,000 yuan, while the generic version of Lucius Pharmaceuticals in Laos has the same specifications and is affordable, only about 850 yuan. For more information about pemetinib, it is recommended to contact a regular overseas medical service agency.

xa0

Reference link: https://medlineplus.gov/druginfo/meds/a620028.html